InferVision

Infervision is an AI medical technology company established in 2016. It focuses on improving multi-disciplinary services and operations with AI, helping healthcare providers in disease screening and diagnosis, patient treatment and management, and research and development. Its product families include InferRead® for disease screening and diagnosis, InferOperate® for intervention and treatment, InferCare® for patient health management, and InferScholar® and InferMatrix for teaching and research. The company states it serves hospitals, other medical institutions, governments, doctors and patients across the globe.

Infervision was founded in 2016. According to the company's own journey timeline, 2016 also saw completion of angel financing and Series A and B financing, and recognition as a National High-Tech Company. In 2017, US, Europe and Japan offices were established, Series B+ and C financing were completed, and the company began participating in world-renowned radiology conferences (ECR, CCR, RSNA, etc.). In 2020, the company states it fought the COVID-19 pandemic with AI technology and obtained four main marketing approvals: CE, PMDA, FDA and NMPA; InferRead® CT Stroke received 510(k) clearance from the FDA; and a product was procured by the European Commission and included in the medical devices ordering list under the Global Drug Facility (GDF) hosted by the United Nations Office for Project Services (UNOPS). In 2022, InferRead® CT Fracture and InferRead® CT Stroke received NMPA Class III medical device approval.

A leading AI medical technology company offering AI-assisted software across screening, diagnosis, treatment, patient management and research.

• InferRead® CT Lung

  Lung nodule detection from chest CT; CE marked, FDA cleared, NMPA approved, UKCA marked

• InferRead® DR Chest

  Detect chest abnormality from chest x-ray; CE marked, UKCA marked

• InferRead® CT Coronary

  Identify coronary artery stenosis in coronary CTA; CE marked, NMPA approved, UKCA marked

• InferRead® CT Stroke

  Triage hemorrhage from brain CT; CE marked, FDA cleared, NMPA approved, UKCA marked

• InferRead® CT Bone

  Identify chest fracture from chest CT; CE marked, NMPA approved, UKCA marked

• InferRead® CT Pneumonia

  Identify and triage pneumonia from chest CT; CE marked, NMPA approved, UKCA marked

• InferOperate® Thorax Planning

  3D reconstruction for thoracic surgery

• InferOperate® Liver Planning

  3D reconstruction for liver surgery

• InferOperate® Urology Planning

  3D reconstruction for urological surgery

• InferCare®

  For patient management and image follow up

• InferScholar®

  AI-enabled Medical Research Platform

• InferMatrix

  AI-enabled Medical Application Platform

• 2021.08.13

  Reported2021.08.13

  InferVision completes Series D2 financing[5]InferVision完成D2轮融资prnewswire.com

  InferVision announced completion of its Series D2 financing, led by Goldman Sachs Asset Management. The company said it had raised around US$140 million in total through its Series D1 and D2 financing rounds.

• 2019.11.13

  Reported2019.11.13

  Infervision releases InferTest[6]Infervision发布InferTestprnewswire.com

  Infervision announced the release of InferTest, a no-fee application intended to let healthcare providers experience AI in their practices.

Read more

1. 1Infervision - Homepageglobal.infervision.com
2. 2Infervision - Company | About Usglobal.infervision.com
3. 3Infervision - News and Eventsglobal.infervision.com
4. 4Infervision - Product Overviewglobal.infervision.com
5. 5InferVision完成D2轮融资prnewswire.com
6. 6Infervision发布InferTestprnewswire.com
7. 7Infervision Launches InferTest and Emphasizes Medical Imaging AI Educationitnonline.com